Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q3

4564.TEDINET S100SU6F
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥466m2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥700m2022-04-01 → 2022-12-31Cons.Net sales
Operating income−¥973m2023-04-01 → 2023-12-31Cons.Operating income
Operating income−¥905m2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income−¥986m2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥929m2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax−¥985m2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax−¥912m2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥987m2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥913m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income−¥987m2023-04-01 → 2023-12-31Cons.Profit loss
Net income−¥913m2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥931mat 2023-12-31Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥1.4bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥275mat 2023-12-31Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥656mat 2023-12-31Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.1bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥599mat 2023-12-31Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥-4.682023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.272023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.742022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio62.3%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥206,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥206,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥261m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥466m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥466m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-12-31−¥175m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-12-31¥634,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-12-31¥427,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥206,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-12-31−¥537m
—segment totalrevenue2023-04-01 → 2023-12-31¥466m
—segment totalrevenue external2023-04-01 → 2023-12-31¥466m
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥206,000
—segment totalsegment profit2023-04-01 → 2023-12-31−¥712m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥290m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥79m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥172,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥536m
—segment totalrevenue2022-04-01 → 2022-12-31¥700m
—segment totalrevenue external2022-04-01 → 2022-12-31¥700m
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥172,000
—segment totalsegment profit2022-04-01 → 2022-12-31−¥615m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 312
ItemContextValueUnit
Relocation expenses noePrior1YTDDuration16161000JPY
Relocation expenses noeCurrentYTDDuration－JPY
Non operating expensesPrior1YTDDuration24176000JPY
Non operating expensesCurrentYTDDuration13713000JPY
Ordinary incomePrior1YTDDuration-928906000JPY
Ordinary incomeCurrentYTDDuration-986439000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration37755000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration3575000JPY
Extraordinary incomePrior1YTDDuration37755000JPY
Extraordinary incomeCurrentYTDDuration3575000JPY
Impairment loss elPrior1YTDDuration20398000JPY
Impairment loss elCurrentYTDDuration2627000JPY
Extraordinary lossPrior1YTDDuration20398000JPY
Extraordinary lossCurrentYTDDuration2627000JPY
Income before income taxesPrior1YTDDuration-911549000JPY
Income before income taxesCurrentYTDDuration-985491000JPY
Income taxes currentPrior1YTDDuration1986000JPY
Income taxes currentCurrentYTDDuration1837000JPY
Income taxes deferredPrior1YTDDuration-338000JPY
Income taxes deferredCurrentYTDDuration－JPY
Income taxesPrior1YTDDuration1648000JPY
Income taxesCurrentYTDDuration1837000JPY
Profit lossPrior1YTDDuration-913197000JPY
Profit lossCurrentYTDDuration-987329000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-913197000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-987329000JPY
Profit lossPrior1YTDDuration-913197000JPY
Profit lossCurrentYTDDuration-987329000JPY
Comprehensive incomePrior1YTDDuration-913197000JPY
Comprehensive incomeCurrentYTDDuration-987329000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-913197000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-987329000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember8666000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember691023000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember699689000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration699689000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember172000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember172000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-172000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember8838000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember691023000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember699862000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-172000JPY
Net salesPrior1YTDDuration699689000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-536143000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-79300000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember-615443000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass